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Objective: To study the inﬂuence of curcumin on chemosensitivity of nephroblastoma
cells.
Methods: Human nephroblastoma cells line SK-NEP-1 was transplanted to the nude
mice subcutaneously to establish the implantation tumor model of human nephroblastoma
cells. A total of 30 tumor-bearing mice were divided into three groups of ten randomly.
The routine chemotherapy group was given vincristine (0.05 mg/mL$0.2 mL/d) and
actinomycin D (15 ng/mL$0.2 mL/d) combined chemotherapy regime. The curcumin
chemotherapy group was given the same combined chemotherapy regimens and curcu-
min (30 mg/kg/d) by intraperitoneal injection. The control group was given normal saline
(NS) of the same volume by intraperitoneal injection. Continuous administration would
be kept for 4 weeks and 3 days a week. The volumetric changes of every group were
recorded. The serum of every group in different time was collected and the VEGF content
was detected by ELISA. All mice were cercriﬁced and the tumor tissues were stripped
and weighed after 4 weeks' treatment. The tumor inhibition rate was calculated. The cell
proliferation activity and apoptosis rate were detected by MTT and ﬂow cytometry
method. All data were statistically analyzed by SPSS 19.0.
Results: The tumor volume, serum VEGF content, tumor inhibition rate, cell prolifer-
ation activity and apoptosis rate of routine chemotherapy group and curcumin chemo-
therapy group had signiﬁcant differences comparing with the control group (P < 0.05)
after 4-week's treatment. The cancer growth of curcumin chemotherapy group was
obviously decreased and even tended to shrink comparing with routine chemotherapy
group (c2 = 15.732, P = 0.007). The cell proliferation activity was signiﬁcantly reduced
and the apoptosis rate was signiﬁcantly higher, (c2 = 9.427, P = 0.012) which showing
the effect of chemotherapy was enhanced.
Conclusions: The chemosensitivity of nephroblastoma cells could be improved by
curcumin, then the effect of preoperative adjuvant chemotherapy scheme would be
enhanced, the growth of nephroblastoma cells would be inhibited and the surgical risk of
nephroblastoma would be reduced.1. Introduction
Nephroblastoma is one of the most common malignant tu-
mors in children. The incidence of this tumor is only second toneuroblastoma. Pathogenesis is generally considered to be
chromosomal deletions or familial inheritance [1], resulting in
the differentiation disorder and malignant proliferation of
blastemal cells. Thus, the age of onset is generally less than 5
years old, a few are less than 10 years old [2]. In the early
stage of the disease, the survival rate is low due to the overall
backwardness of tumor clinical research. In recent years,
compared with the cure rate of malignant tumors in adults,
related researches have improved the cure rate of this disease
signiﬁcantly. Modern clinical treatment measures areer the CC BY-NC-ND license (http://
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year's survival rate is generally above 80%. Studies have shown
that preoperative adjuvant chemotherapy could effectively
reduce the surgical risk of nephroblastoma and improve the
prognostic effects [3]. Therefore, preoperative chemotherapy
has a pivotal position in the whole process of treatment.
Currently, limited drugs used for children's tumor
chemotherapy are mainly vincristine, actinomycin D,
adriamycin Amycin etc. [4,5]. Chemotherapy adapts one or
more drugs according to tumor stage, and the effect are
different because of children's individual factors. Therefore,
the study of nephroblastoma aims to explore a new and
effective adjuvant chemotherapy scheme, and improve the
effect of preoperative chemotherapy and chemosensitivity.
Curcumin, extracted from curcuma, is an important
component of Chinese medicine with the effect of softening
heart and cerebral vessels, antioxidation, antisepsis, anti-
inﬂammation and regulating the digestive system [6]. Studies
have shown that this compound can inhibit the malignant
proliferation of tumor cells [7,8], and enhance
chemosensitivity of liver cancer, gastric cancer and colon
cancer etc. [9,10], but the research applied to pediatric tumor
is rare. This study provides theoretical and experimental
basis for the study of new adjuvant chemotherapy, by
establishing the implantation tumor model of nephroblastoma
cells and implementing different chemotherapy schemes to
research the inﬂuence of curcumin on chemosensitivity of
nephroblastoma cells.
2. Materials and methods
2.1. Materials
Nude mice used in the experiment were purchased from
Shanghai Experimental Animal Center, Chinese Academy of
Sciences. A total of 36 mice which were 4–5 weeks old were
used for this study. Half of then were male mice and half were
female mice. The study was performed after the mice were
allowed to acclimate for 1 week at Animal Experimental Center
of Zhengzhou University. Laboratory was kept sterilized with
constant temperature and humidity.
Human nephroblastoma cell line SK-NEP-1 was purchased
from the Shanghai Cell Bank, Chinese Academy of Sciences.
Curcumin was purchased from Sigma Company. RPMI-1640
and fetal bovine serum were purchased from GIBCIO Com-
pany. Rat VEGF ELISA kit was purchased from Santa Cruz
Company; DMSO and MTT were purchased from Sigma
Company. FITC, and PI were purchased from BD (Shanghai)
Co., ltd. Among them, curcumin was dissolved in 10%
DMSO- normal saline before 30 mg/kg clear liquid was
formulated.
2.2. Methods
2.2.1. Implantation tumor model
The cell cryopreserved tubes were placed in the 37 C water
bath and shaken for thawing out. The cell suspension was
transferred to culture bottles with suction tubes and then cultured
in RPMI-1640 medium after adding 10% fetal bovine serum and100 U/mL penicillin and streptomycin. Cells were digested by
trypsin every other day and the culture medium was replaced to
log phase.
The cell concentration was adjusted to 1 × 107/mL. Before
the experiment, right forelimbs of mice were disinfected by
iodine, and injected with 0.1 mL cell suspension in 1 mL sterile
syringes. After implantation, mice were under close observation
for 30 min, and were put back to the cage without adverse
reaction.
2.2.2. Treatment in each group
After 7–10 days, 30 mice implanted tumor models were
divided into 3 groups. They are routine chemotherapy group,
curcumin chemotherapy group and control group respectively.
The routine chemotherapy group was intraperitoneally injected
with vincristine (0.05 mg/mL$0.2 mL/d) and actinomycin D
(15 ng/mL$0.2 mL/d). Continuous administration was 3 days a
week and kept for 4 weeks. The curcumin chemotherapy group
was given the same combined chemotherapy regimens and
curcumin (30 mg/kg/d) by intraperitoneal injection. Contin-
uous administration was 3 days a week and kept for 4 weeks.
The control group was given normal saline (NS) of the same
volume by intraperitoneal injection. After treatment, tumor's
long (a) and short diameters (b) were measured every 3 days,
and the tumor volume was calculated with the formula
V = 0.5 × ab2.
2.2.3. Detection of the VEGF content
two mice were randomly selected 1day before treatment and
7 d, 14 d, 21 d and 28 d after treatment, and 2 mL peripheral
blood were drew by femoral artery blood sampling method. The
serum was obtained after 3 000 rpm centrifugation, and the
VEGF protein content in serum samples was detected by ELISA.
The speciﬁc operating steps were carried out according to the
instructions of kit.
2.2.4. Cells proliferation activity
After 4 weeks' chemotherapy, all mice were sacriﬁced with
cervical dislocation and the tumor tissues were stripped and
weighed immediately. The tumor inhibition rate was calculated
as:
Tumor inhibition rate = (tumor weight of control group − tumor
weight of experimental group)/tumor weight of control
group × 100%.
Cells suspension was made from tumor specimens and
cultured in DMEM medium containing 20% fetal bovine
serum and 1% of penicillin and streptomycin. After 48 h,
20 uL MTT was added to absorb culture medium. Four hours'
later, the supernatant was discarded after centrifugation.
150 uL DMSO was added to terminate the reaction. The
absorbance at 490 nm was detected by ELIASA and the cell
activity was detected comparing with the absorbance of control
hole.Cell relative proliferation activity (%) = absorbance of experi-
mental group/absorbance of control group × 100%.
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1.5 × 105/L tumor cells were inoculated in culture ﬂasks
and washed two times with PBS. Then 100 uL Binding Buffer
and 5 uL Annexin-V (20 ug/mL) marked by FITC were added.
They were gently mixed together and incubated for 15 min at
4 C without light, then added 5 uL PI (50 ug/mL) into them.
After reacting for 5 min without light, 400 uL Binding Buffer
was added into. Apoptosis rate (within 1 h) were detected by
ﬂow cytometry (model: EPICS-ELITE-ESP).
2.3. Experimental ethics statement
All experiments in the study were conducted according to the
guidelines on animal healthcare and use of animal experimental
center of Zhengzhou University in Henan Province and
approved by local ethics committee and conformed to the
guidelines on healthcare and use of experimental animals made
by National Institutes of Health (Publication No. 85 – 23,
revised in 1985).
3. Results
3.1. Comparing the efﬁcacy in each group
Ten days after implantation tumor model, 100 mm3 tumor
had been founded under the skin of mice. After different
treatment, the changes of tumor volume in each group were
shown in Table 1. From the table, we could see that the tumor
volume of routine chemotherapy group and curcumin
chemotherapy group were signiﬁcantly smaller than that of the
control group (P < 0.05). 28d later, all mice were cercriﬁced
and the tumor tissues were stripped and weighed. The tumor
weight of control group was (0.75 ± 0.36) g, the tumor weight
of routine chemotherapy group was (0.27 ± 0.11) g, and the
inhibition rate was 63.8%; the tumor weight of curcumin
chemotherapy group was (0.14 ± 0.07) g, and the inhibition
rate was 81.3%.
The content of vascular endothelial growth factor (VEGF)
was closely related to the prognosis of tumor. The serum VEGF
content of each group had no signiﬁcant differences before
treatment (P > 0.05). The VEGF content of each group at
different times were shown in Table 2. The serum VEGF content
of chemotherapy group and VCR chemotherapy group were
signiﬁcantly lower than control group after 2-week's treatment. 4
weeks later, the VEGF content of chemotherapy group and
curcumin chemotherapy group were lower than control group,
and there was signiﬁcant difference between ﬁrst two groups
(P < 0.01).
3.2. The cell proliferation activity and apoptosis rate in
each group
The cell proliferation activity and apoptosis rate were
detected by MTT and ﬂow cytometry method (Table 3). We
could see that the proliferation activity of chemotherapy group
and curcumin chemotherapy group was signiﬁcantly lower than
control group, but the apoptosis rate of them was higher than
control group. The effect of inhibiting tumor cell proliferation on
curcumin chemotherapy group was more obvious than routine
chemotherapy group.T T * P
Table 2
VEGF content of each group at different times (Mean ± SD, ng/mL).
Group 7 d 14 d 21 d 28 d
Control group 575.63 ± 28.32 586.34 ± 29.34 601.32 ± 30.14 616.24 ± 21.24
Coutine chemotherapy group 403.54 ± 19.63* 352.34 ± 17.21* 291.63 ± 16.32* 234.31 ± 31.24*
Curcumin chemotherapy group1 384.51 ± 18.62* 303.67 ± 15.21*▽ 153.67 ± 8.21
*
▽ 86.45 ± 5.23
*
▽
*P < 0.05 compared with control group; ▽P < 0.05 compared with routine chemotherapy group;
1compared with routine chemotherapy group
c2 = 26.374.
Table 3
The cell proliferation activity and apoptosis rate in each group (%).
Group Proliferation index Apoptosis rate
Routine chemotherapy
group
15.69 ± 5.21* 22.37 ± 8.96*
Curcumin chemotherapy
group
11.57 ± 4.25*▽
1 37.23 ± 12.68*▽
2
Control group 33.74 ± 10.68 14.21 ± 5.14
*P < 0.05, compared with control group; ▽P < 0.01 compared with
routine chemotherapy group; 1compared with routine chemotherapy
group; c2 = 10.542; 2compared with routine chemotherapy group
c2 = 9.427.
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Preoperative adjuvant chemotherapy is an effective treatment
to reduce the surgical risk of nephroblastoma and obtain good
prognosis. But because of drug resistance of tumor cells,
sometimes the conventional chemotherapy is hard to obtain
satisfactory effect [11]. Curcumin is a kind of polyphenolic
compounds extracted from zingiberaceae plants [12]. Surveys
and experimental researches showed that Curcumin has a
variety of clinical medical value in inﬂammation,
cardiovascular and digestive system, and plays a positive role
in resisting the occurrence and development of tumor [13,14].
Curcumin can not only inhibit the growth of many tumor
cells, but also enhance the sensitivity of chemotherapy and
radiotherapy of breast cancer cells, cervical cancer cells etc.
[15,16]. Studies have conﬁrmed that curcumin also can enhance
the chemosensitivity of malignant glioblastoma and
neuroblastoma, and prevent cancer cells from transferring to
other parts and promoting apoptosis [17], but the researches on
curcumin which are used for chemotherapy of nephroblastoma
cells are insufﬁcient. This study used curcumin combined with
vincristine and actinomycin D to treat neuroblastoma. The
results showed that after adding curcumin chemotherapy,
curcumin on inhibiting tumor growth in mice was more
signiﬁcant than routine chemotherapy group (P < 0.05 or
0.01). In addition, we found that the serum VEGF content of
tumor-bearing mice in curcumin chemotherapy group was less
than routine chemotherapy group by detecting the VEGF content
as tumor marker in tumor bearing mice (P < 0.05). And after 4-
week's treatment, the serum VEGF content of curcumin
chemotherapy group was close to normal mice.
The speciﬁc mechanism of curcumin on tumor has not been
clearly studied yet. Now, the basic conclusion we have reached
is that this material can promote the generation of fast reactive
oxygen in cells, promote cells secreting lots of apoptosis
inducing factor (AIF), activate the apoptosis pathway of
Caspase-3, and inhibit the malignant proliferation of cancer
cells effectively [18]. Chang et al. [19] also found that curcumincould activate signaling pathway of ROS/Cyto-C/Caspase-3
and promote osteosarcoma cell MG63 tending to apoptosis.
Ai et al. [20] conﬁrmed that the mechanism of activating
Caspase signaling pathway by curcumin is to stimulate
mitochondria secreting AIF in cells and promote tumor cells
such as melanoma tending to apoptosis. In addition, Yang
et al. [21] found that curcumin could reduce the expression
content of tumor protein STAT3 and IL-6, inhibit the malig-
nant proliferation and metastasis of non small cell lung cancer.
Li et al. [22] found that curcumin could down regulate
oncogenic gene MDM2 by PI3K/mTOR/ETS2 signaling
pathway, up regulate the expression of anti oncogene p21,
and play a role in anti-tumor and enhancing the sensitivity
to chemotherapy and radiotherapy of tumor cells. Fan et al.
[23] found that curcumin was the inhibitor of fatty acid
synthase (FAS), and played a role in anti-tumor and
enhancing the chemosensitivity by inhibiting the expression of
tumor protein in liver cancer. Therefore, it could be seen that
the curcumin in different tumor tissues were related to the
apoptotic pathway, but its anti-tumor effect modes were
different. Therefore, the speciﬁc mechanism which curcumin
increases chemosensitivity of nephroblastoma cells still need
to be studied and conﬁrmed by relevant molecular
experiments.
In summary, for nephroblastoma, curcumin has an unique
antitumor effect, and plays a synergistic role with routine
chemotherapy drugs. The mechanism for enhancing chemo-
sensitivity of cells is to activate the related apoptosis pathway. In
the research, tumor bearing mice were given curcumin by
intraperitoneal injection which enhanced the chemotherapy ef-
fect of conventional chemotherapy drugs such as vincristine, but
in actual clinical trial, further studies were needed to make sure
suitable dosage of curcuminto anti tumor and related side ef-
fects; Therefore, in further experiments, we need to design
different curcumin doses or courses of treatment, to seek the best
preoperative auxiliary chemotherapy for nephroblastoma, reduce
the surgical risk and improve the prognosis effect.
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